2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Locatelli, F. Articles by Del Vecchio, L. Search for Related Content PubMed PubMed Citation Articles by Locatelli, F. Articles by Del Vecchio, L.

Renal Manifestations in the Metabolic Syndrome

Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy

Address correspondence to: Prof. Francesco Locatelli, Department of Nephrology and Dialysis, A. Manzoni Hospital, Via dell’Eremo 9/11, 23900 Lecco, Italy. Phone: +39-0341-489850; Fax: +39-0341-489860; E-mail: nefrologia{at}ospedale.lecco.it

The metabolic syndrome, which is characterized by obesity, serum lipid profile alterations, hypertension, and fasting hyperglycemia, is very common in developed countries, and its prevalence is likely to increase. Chronic kidney disease (CKD) also has become a significant public health problem because it affects a considerable proportion of the adult population and is a major risk factor for cardiovascular disease and premature death. Although it is widely known that the metabolic syndrome is a major risk factor for the development of type 2 diabetes and cardiovascular disease, its precise relationship with the risk for renal impairment only recently has been clarified: Patients with the metabolic syndrome are at significantly higher risk for microalbuminuria and/or CKD, and the level of risk is related to the number of components of the syndrome itself. Although it is difficult to discriminate the detrimental renal effects of the metabolic syndrome from those of hypertension and impaired glucose metabolism, its other aspects (particularly obesity) may favor independently the development of renal abnormalities and may be considered new modifiable risk factors for CKD. These observations provide a rationale for intervention studies that aim to verify whether treating the many components of the metabolic syndrome can effectively prevent the development and progression of renal damage.

This article has been cited by other articles:

				P. Korantzopoulos, M. Elisaf, and H. J. Milionis Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2768 - 2774. [Full Text] [PDF]

				N. M. Maalouf, M. A. Cameron, O. W. Moe, B. Adams-Huet, and K. Sakhaee Low Urine pH: A Novel Feature of the Metabolic Syndrome Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 883 - 888. [Abstract] [Full Text] [PDF]

				Ar. Mani, J. Radhakrishnan, H. Wang, Al. Mani, M.A. Mani, C. Nelson-Williams, K.S. Carew, S. Mane, H. Najmabadi, D. Wu, et al. Metabolic Syndrome--What We Know and What We Don't Know: LPR6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. Science 315: 1278-1282, 2007 J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1619 - 1623. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673